These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16632435)

  • 1. Mediterranean diet, olive oil and cancer.
    Colomer R; Menéndez JA
    Clin Transl Oncol; 2006 Jan; 8(1):15-21. PubMed ID: 16632435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9).
    Menendez JA; Lupu R
    Curr Pharm Biotechnol; 2006 Dec; 7(6):495-502. PubMed ID: 17168666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
    Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
    Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleic acid suppresses overexpression of ERBB2 oncogene.
    Nelson R
    Lancet Oncol; 2005 Feb; 6(2):69. PubMed ID: 15704291
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
    Menendez JA; Vazquez-Martin A; Garcia-Villalba R; Carrasco-Pancorbo A; Oliveras-Ferraros C; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2008 Dec; 8():377. PubMed ID: 19094209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?
    Colomer R; Lupu R; Papadimitropoulou A; Vellón L; Vázquez-Martín A; Brunet J; Fernández-Gutiérrez A; Segura-Carretero A; Menéndez JA
    Clin Transl Oncol; 2008 Jan; 10(1):30-4. PubMed ID: 18208790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effects and molecular mechanisms of olive oil and other dietary lipids in breast cancer.
    Escrich E; Solanas M; Moral R; Escrich R
    Curr Pharm Des; 2011; 17(8):813-30. PubMed ID: 21443482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Colomer R; Lupu R
    J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab.
    Goldblatt EM; Erickson PA; Gentry ER; Gryaznov SM; Herbert BS
    Breast Cancer Res Treat; 2009 Nov; 118(1):21-32. PubMed ID: 18853252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    Baumann J; Wong J; Sun Y; Conklin DS
    BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
    Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
    Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.